Presentation Type: Poster
Abstract: It is estimated that mortality due to cancer reach to 13.1 million in 2030. Breast cancer is the top cancer in women both in the developed and the developing world. The incidence of breast cancer is increasing in the developing world due to increase life expectancy, increase urbanization and adoption of western lifestyles. The conventional cancer treatment approach are chemotherapy, as a result of, and surgery. Each of these methods problems such as side effects, increasing the dose of radiation and their recurrence. Cancer nanotechnology is an interdisciplinary area of research in medicine with broad applications for molecular imaging, molecular diagnosis, and targeted therapy. In vivo early detection of cancer is the most important factor in the success of a therapy. After exposure functionalized supermagnetic iron oxide nanoparticles (SPIONPs) to a magnetic field they are able to identify circulating tumor cells (CTC). The accumulation of nanoparticles in tumor tissue via enhanced permeability and retention (EPR) effect will help not only diagnosis but also to cancer treatment more effectively. Anthracycline-based nanoformulations, liposomal daunorubicin, nonpegylated liposomal doxorubicin, and PEGylated liposomal doxorubicin are the first nanoparticles applied in medicine as drug delivery systems. Nanotechnology use exogenous and endogenous contrast agent to diagnose of cancer tissue. Hypoxia in cancer tissues is an endogenous contrast agent that can be detected by optical coherence tomography (OCT) method. Nanocarrier with cell-penetrating peptides (CPT) coating (as active targeting), can be increased uptake of nanoparticles with tumor cells. Multiple drug resistance in cancer cells is one of the difficulties ahead of cancer treatment. To overcome this problem, cancer nanotechnology use PEGylated nanoparticle (to pass through the P-glycoprotein (Pgp) pump without being detected) or nanoparticle with endocytosis capability.